Eastbourne Syncope Assessment Study II (EaSyAS II)
Primary Purpose
Syncope
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Sleuth Implantable Loop Recorder
Other
Sponsored by
About this trial
This is an interventional diagnostic trial for Syncope focused on measuring Implantable Loop Recorder, Home monitoring, Syncope/ Falls Clinic
Eligibility Criteria
Inclusion Criteria:
- Age > = 16 yrs
- Acute syncope presentation to MAU or A+E
- 2 or more unexplained syncopes within the past 24 months including index episode
- Normal baseline ECG
- Absence of co - existing pathology requiring admission
Exclusion Criteria:
- Suspected or known heart disease
- ECG abnormalities suspected of arrhythmic syncope listed in Table 1
- Syncope occurring during exercise
- Syncope causing severe injury
- Family history of sudden death
- Sudden onset palpitations prior to syncope
Table 1: ECG Abnormalities:
- Bifascicular block (defined as LBBB or RBBB combined with left anterior or left posterior fascicular block)
- Other intraventricular abnormalities (QRS duration >= 0.12s)
- Mobitz 1 second degree AV block (Wenckebach)
- Asymptomatic sinus bradycardia (<50 bpm), SA node or sinus pause >= 3s in the absence of negatively chronotropic medications
- Pre-excited QRS with short PR interval (WPW)
- Significantly Prolonged QT interval
- RBBB pattern with ST elevation in V1 - V3 (Brugada Syndrome)
- Negative T waves with ST segment elevation in right precordial leads suggestive of arrythmogenic right ventricular dysplasia
- Significant Q waves (>= 0.02s) suggestive of MI
Sites / Locations
- Cardiology Department, Eastbourne General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
ILR + Syncope Clinic
ILR Only
Routine Mx + Syncope Clinic
Routine Mx
Arm Description
Patients will have ILR implanted and follow-up in Syncope Clinic
Patients will have ILR implanted and routine follow up.
Patients will receive routine care and management plus follow up in Syncope Clinic
Patients will receive routine care and management
Outcomes
Primary Outcome Measures
Primary Outcome 1. Time to ECG (objective) diagnosis of syncope
Secondary Outcome Measures
1. Time to ECG directed therapy. 2. Time to introduction of empiric therapy. 3. Time to first post induction syncope. 4. Cost effectiveness analysis.
Full Information
NCT ID
NCT00517023
First Posted
August 15, 2007
Last Updated
May 6, 2008
Sponsor
Eastbourne General Hospital
Collaborators
Transoma Medical, East Sussex National Health Service Trust, United Kingdom
1. Study Identification
Unique Protocol Identification Number
NCT00517023
Brief Title
Eastbourne Syncope Assessment Study II
Acronym
EaSyAS II
Official Title
Eastbourne Syncope Assessment Study II
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Unknown status
Study Start Date
August 2007 (undefined)
Primary Completion Date
July 2008 (Anticipated)
Study Completion Date
August 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Eastbourne General Hospital
Collaborators
Transoma Medical, East Sussex National Health Service Trust, United Kingdom
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Syncope (commonly called collapses or blackouts) is defined as loss of consciousness which is transient, self limiting and usually leads to falling.
While the causes of syncope encompass a wide variety of factors, those due to heart rhythm abnormalities are acknowledged to be significantly more serious compared with other causes.
The main aim of the study is to see if it is possible to find the cause of a patient's syncope faster using a device called an implantable loop recorder (ILR), which is implanted under the skin, versus conventional management. The device is slightly larger than a 50 pence coin and records the rhythm of the heart continuously.
Although ILRs are being used widely today, we want to use a new model that is able to relay information to the doctor via wireless technology and internet.
We also want to use ILRs earlier in diagnosing syncope, thereby avoiding unnecessary and lengthy hospital admissions and lowering cost.
Primary aim: To see how soon the ILR detects abnormal heart rhythms or normal ones (in study subjects who faint/ suffer syncope).
Secondary aims are:
To see how soon treatment is started once the abnormal rhythm is detected by the ILR.
To see which group (patients with ILRs or those receiving conventional tests) receives treatment sooner.
To see which group has less subsequent collapses i.e has benefited from appropriate treatment sooner.
To assess the cost effectiveness of using the implantable loop recorder more as a diagnostic tool for syncope versus conventional management (it should save many hospital admissions).
Detailed Description
The original EaSyAS study (1998) evaluated the use of implantable loop recorders (ILRs) in the diagnosis and management of syncope.This demonstrated a significant increase in successful diagnosis following use of implantable loop recorders. Here there were 442 syncope admissions to Eastbourne in 2001. Diagnostic rate was 42%. In addition, time to diagnosis was quicker and therefore so was introduction of therapy. This resulted in significant increase in time to recurrent syncopal episodes and improved general wellbeing in an unselected population with syncope of an unknown cause.
The "Post-EaSyAS" study evaluated extended (2.5 years) follow up of these patients. The "Tis-EaSyAS" study evaluated 3 different tilt protocols with long term ILR follow up describing the positive predictive value of tilt testing in unexplained syncope.
The EaSyAS II study elaborates further the above by using the ILR to avoid hospital admission and optimise the use of a falls/syncope clinic, potentially improving cost effective diagnosis and management of syncope.
ILRs will be implanted without patient admission and with follow up in a syncope/falls assessment clinic, compared to optimal protocol driven current management.
The ILR used has capabilities to record and transmit heart rhythm abnormalities to a wireless receiver which will then relay the information to the clinician via the internet. It is hoped that this will shorten diagnosis times and speed up commencement of treatment for patients, and will avoid expensive tests and more expensive hospital admissions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Syncope
Keywords
Implantable Loop Recorder, Home monitoring, Syncope/ Falls Clinic
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ILR + Syncope Clinic
Arm Type
Active Comparator
Arm Description
Patients will have ILR implanted and follow-up in Syncope Clinic
Arm Title
ILR Only
Arm Type
Active Comparator
Arm Description
Patients will have ILR implanted and routine follow up.
Arm Title
Routine Mx + Syncope Clinic
Arm Type
Active Comparator
Arm Description
Patients will receive routine care and management plus follow up in Syncope Clinic
Arm Title
Routine Mx
Arm Type
Active Comparator
Arm Description
Patients will receive routine care and management
Intervention Type
Device
Intervention Name(s)
Sleuth Implantable Loop Recorder
Intervention Description
ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
Intervention Type
Other
Intervention Name(s)
Other
Intervention Description
Routine care and tests usually offered for syncope patients.
Primary Outcome Measure Information:
Title
Primary Outcome 1. Time to ECG (objective) diagnosis of syncope
Time Frame
1 Year
Secondary Outcome Measure Information:
Title
1. Time to ECG directed therapy. 2. Time to introduction of empiric therapy. 3. Time to first post induction syncope. 4. Cost effectiveness analysis.
Time Frame
1 Year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > = 16 yrs
Acute syncope presentation to MAU or A+E
2 or more unexplained syncopes within the past 24 months including index episode
Normal baseline ECG
Absence of co - existing pathology requiring admission
Exclusion Criteria:
Suspected or known heart disease
ECG abnormalities suspected of arrhythmic syncope listed in Table 1
Syncope occurring during exercise
Syncope causing severe injury
Family history of sudden death
Sudden onset palpitations prior to syncope
Table 1: ECG Abnormalities:
Bifascicular block (defined as LBBB or RBBB combined with left anterior or left posterior fascicular block)
Other intraventricular abnormalities (QRS duration >= 0.12s)
Mobitz 1 second degree AV block (Wenckebach)
Asymptomatic sinus bradycardia (<50 bpm), SA node or sinus pause >= 3s in the absence of negatively chronotropic medications
Pre-excited QRS with short PR interval (WPW)
Significantly Prolonged QT interval
RBBB pattern with ST elevation in V1 - V3 (Brugada Syndrome)
Negative T waves with ST segment elevation in right precordial leads suggestive of arrythmogenic right ventricular dysplasia
Significant Q waves (>= 0.02s) suggestive of MI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
A N Sulke, DM FRCP FESC FACC
Phone
+44 1323 417400
Ext
5869
Email
neil.sulke@esht.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A N Sulke, DM FRCP FESC FACC
Organizational Affiliation
Eastbourne General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology Department, Eastbourne General Hospital
City
Eastbourne
State/Province
East Sussex
ZIP/Postal Code
BN21 2UD
Country
United Kingdom
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Eastbourne Syncope Assessment Study II
We'll reach out to this number within 24 hrs